108 results
DEF 14A
MREO
Mereo Biopharma Group Plc
24 Apr 24
Definitive proxy
7:30am
which time he was involved in the safety and efficacy review of hundreds of drugs. Most recently Dr. Shames served as Deputy Director, Office of Drug
10-K
2023 FY
EX-10.30
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
efficacy, safety, patent and regulatory exclusivity, anticipated or approved labeling, present and future market potential, competitive market conditions … . Halting enrolment due to a safety issue or request by a Regulatory Authority will not be considered to be Completion of Enrolment;
“Confidential
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
for leflutrozole for the treatment of HH and in December 2018, we reported positive results from the safety extension study for leflutrozole. In December 2023 we … . There were no cardiac-related safety concerns observed in the study.
Top-line Data from Setrusumab Phase 2 Portion of Phase 2/3 Orbit Study
In June
8-K
EX-99.1
MREO
Mereo Biopharma Group Plc
27 Mar 24
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
4:08pm
development. Etigilimab (anti-TIGIT) has completed a Phase 1b/2 basket study evaluating its safety and efficacy in combination with an anti-PD-1 in a range
8-K
EX-99.1
MREO
Mereo Biopharma Group Plc
8 Jan 24
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
7:08am
a Phase 1b/2 basket study evaluating its safety and efficacy in combination with an anti-PD-1 in a range of tumor types including three rare tumors
6-K
EX-3.1
uk1a20q trsp5ps
18 Dec 23
Current report (foreign)
4:10pm
6-K
EX-99.1
7oo m3cgys4hlse9r
23 Oct 23
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
4:08pm
6-K
EX-99.1
ple3hk9wq apxnr26p
17 Oct 23
Current report (foreign)
7:01am
6-K
dhiclhgh50gao5jg2
17 Oct 23
Current report (foreign)
7:01am
6-K
EX-99.2
2awb1b h3sm0878q1
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.3
yctmrx
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.1
vblqylalreamf8
6 Jul 23
Ultragenyx Announces First Patients Dosed in Phase 3 Program
8:05am
6-K
EX-99.1
blw1mkzi
5 Jun 23
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit
4:37pm
6-K
EX-99.1
h481cl
8 May 23
Current report (foreign)
4:07pm
6-K
EX-99.1
bgmv9qpow6chqbfyk
5 May 23
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
5:06pm
6-K
EX-99.2
jib1at0q hnmez
2 Nov 22
Current report (foreign)
4:17pm
6-K
EX-99.2
2m5pz0l92r8nxm65g
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-99.1
j9hllcfffklk
17 Oct 22
Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of
7:16am
6-K
EX-99.1
0eortn3e blfee4
12 Sep 22
Data support further evaluation of PVR, CD226, and TIGIT as potential biomarkers of enrichment for etigilimab plus anti-PD1 therapy
8:17am
6-K
EX-99.1
kk6i9b9u83hk9t8bc
31 Aug 22
Letter Reiterates Mereo’s Updated Strategic Plan to Maximize Value for All Shareholders and Corrects Rubric’s Assumptions
7:57am